| T cell anergy and costimulation LJ Appleman, VA Boussiotis Immunological reviews 192 (1), 161-180, 2003 | 479 | 2003 |
| CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression LJ Appleman, A Berezovskaya, I Grass, VA Boussiotis The Journal of Immunology 164 (1), 144-151, 2000 | 310 | 2000 |
| Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma TK Choueiri, MN Fishman, B Escudier, DF McDermott, CG Drake, ... Clinical Cancer Research 22 (22), 5461-5471, 2016 | 285 | 2016 |
| Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and … TK Choueiri, S Jacobus, J Bellmunt, A Qu, LJ Appleman, C Tretter, ... Journal of clinical oncology 32 (18), 1889-1894, 2014 | 285 | 2014 |
| CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells LJ Appleman, AAFL van Puijenbroek, KM Shu, LM Nadler, VA Boussiotis The Journal of Immunology 168 (6), 2729-2736, 2002 | 262 | 2002 |
| A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2 JP Eder, GI Shapiro, LJ Appleman, AX Zhu, D Miles, H Keer, B Cancilla, ... Clinical Cancer Research 16 (13), 3507-3516, 2010 | 234 | 2010 |
| First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non … A Patnaik, LJ Appleman, AW Tolcher, KP Papadopoulos, M Beeram, ... Annals of oncology 27 (10), 1928-1940, 2016 | 227 | 2016 |
| Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis TK Choueiri, TM Bauer, KP Papadopoulos, ER Plimack, JR Merchan, ... Nature medicine 27 (5), 802-805, 2021 | 193 | 2021 |
| Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma VS Koshkin, PC Barata, T Zhang, DJ George, MB Atkins, WJ Kelly, ... Journal for immunotherapy of cancer 6, 1-7, 2018 | 174 | 2018 |
| The high-dose aldesleukin “select” trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma DF McDermott, SC Cheng, S Signoretti, KA Margolin, JI Clark, JA Sosman, ... Clinical Cancer Research 21 (3), 561-568, 2015 | 172 | 2015 |
| Cabozantinib, a new standard of care for patients with advanced renal cell carcinoma and bone metastases? Subgroup analysis of the METEOR trial B Escudier, T Powles, RJ Motzer, T Olencki, O Arén Frontera, S Oudard, ... Journal of Clinical Oncology 36 (8), 765-772, 2018 | 142 | 2018 |
| MET signaling pathway: a rational target for cancer therapy LJ Appleman Journal of clinical oncology 29 (36), 4837-4838, 2011 | 122 | 2011 |
| Autophagy inhibition to augment mTOR inhibition: a phase I/II trial of everolimus and hydroxychloroquine in patients with previously treated renal cell carcinoma NB Haas, LJ Appleman, M Stein, M Redlinger, M Wilks, X Xu, A Onorati, ... Clinical cancer research 25 (7), 2080-2087, 2019 | 118 | 2019 |
| Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study AO Siefker-Radtke, A Necchi, SH Park, J García-Donas, RA Huddart, ... The Lancet Oncology 23 (2), 248-258, 2022 | 105 | 2022 |
| Sexuality and cancer: conversation comfort zone RT Penson, J Gallagher, ME Gioiella, M Wallace, K Borden, LA Duska, ... The Oncologist 5 (4), 336-344, 2000 | 88 | 2000 |
| Upregulation of the ATR‐CHEK1 pathway in oral squamous cell carcinomas RA Parikh, LJ Appleman, JE Bauman, M Sankunny, DW Lewis, A Vlad, ... Genes, Chromosomes and Cancer 53 (1), 25-37, 2014 | 85 | 2014 |
| The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment RA Parikh, P Wang, JH Beumer, E Chu, LJ Appleman OncoTargets and therapy, 969-983, 2014 | 83 | 2014 |
| Final results of a phase 1 study of single-agent veliparib (V) in patients (pts) with either BRCA1/2-mutated cancer (BRCA+), platinum-refractory ovarian, or basal-like breast … S Puhalla, JH Beumer, S Pahuja, LJ Appleman, HAH Tawbi, RG Stoller, ... Journal of Clinical Oncology 32 (15_suppl), 2570-2570, 2014 | 80 | 2014 |
| Tumor mutational load and immune parameters across metastatic renal cell carcinoma risk groups G De Velasco, D Miao, MH Voss, AA Hakimi, JJ Hsieh, NM Tannir, ... Cancer immunology research 4 (10), 820-822, 2016 | 75 | 2016 |
| A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer AW Tolcher, LJ Appleman, GI Shapiro, AC Mita, F Cihon, A Mazzu, ... Cancer chemotherapy and pharmacology 67, 751-764, 2011 | 75 | 2011 |
